This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biogen, Genentech's Rituxan Fails New Study

The drug Rituxan failed to benefit patients with lupus, according to negative results from a late-stage study announced Tuesday by the drug's partners, Genentech (DNA) and Biogen Idec (BIIB - Get Report).

This is the second clinical setback for Rituxan in the last two weeks. On April 15, the companies announced that a late-stage study in primary progressive multiple sclerosis also failed.

In this most recent study, patients with systemic lupus erythematosus (SLE), commonly called lupus, failed to respond any better to Rituxan vs. placebo after one year of treatment, the companies said. None of the study's six secondary endpoints were successful, either.

A separate phase III study of Rituxan in patients with lupus nephritis, a different form of the disease, is ongoing.

Lupus has proven to be a stubborn disease to overcome, leaving in its wake a long list of clinical trial failures. With that said, most analysts did not include Rituxan-lupus revenue in their financial models for either Genentech or Biogen Idec.

However, lupus and multiple sclerosis were seen as long-term growth opportunities for Rituxan, so the recent study failures take a bite out of that prospect.

Genentech and Biogen Idec reported 2007 Rituxan sales of $2.29 billion in the U.S., primarily as a treatment for the blood cancer non-Hodgkin's lymphoma. The drug is also approved to treat rheumatoid arthritis.

Genentech shares were down 5.8% at $68.93 in early trading Tuesday. Biogen Idec was trading down 5% at $61.43.

Know What You Own: Genentech has a deep cancer drug pipeline, with about 15 experimental drugs in phase I, II or III trials. Among the biotech company's cancer drug partners are Curis (CRIS - Get Report), Immunogen (IMGN - Get Report), Abbott Labs (ABT - Get Report), Seattle Genetics (SGEN) and Exelixis (EXEL).
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ABT $38.85 0.00%
BIIB $273.69 0.00%
CRIS $2.01 0.00%
EXEL $4.82 0.00%
IMGN $6.61 0.00%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs